NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

For information the company have advised that they will no longer be making a submission, or making this gene therapy available in the UK. Therefore, in collaboration with the company, NICE has ...

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.

There is a simple discount patient access scheme for vamorolone. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

The National Institute for Health and Care Excellence (NICE) is producing guidance on Artificial intelligence technologies to help detect fractures on X-rays in urgent care: early value assessment.

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Vamorolone is recommended, within its marketing authorisation, as an option for treating Duchenne muscular dystrophy (DMD) in people 4 years and over. Vamorolone is only recommended if the company ...

Vamorolone (Agamree, Santhera) is indicated for 'the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older'. The anticipated list price of vamorolone is £4,585.87 per 100 ...